Clinical Trial Update: A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Diabetic Macular Edema and Retinal Vein Occlusion [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for a depot formulation of sunitinib malate (GB-102) in diabetic macular edema and retinal vein occlusion has completed with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema
• Retina Vein Occlusion

Drugs mentioned

• GB-102 (sunitinib malate depot formulation)

Snippet

Sponsor: Graybug Vision | Conditions: Diabetic Macular Edema, Retina Vein Occlusion | Phase 2 | Status: COMPLETED | Results posted: 2021-07-15